Free Trial
NASDAQ:VIGL

Vigil Neuroscience Q1 2025 Earnings Report

Vigil Neuroscience logo
$2.75 +0.19 (+7.42%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$2.70 -0.04 (-1.64%)
As of 05/2/2025 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vigil Neuroscience EPS Results

Actual EPS
N/A
Consensus EPS
-$0.53
Beat/Miss
N/A
One Year Ago EPS
N/A

Vigil Neuroscience Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vigil Neuroscience Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 6, 2025
Conference Call Time
9:30AM ET

Conference Call Resources

Vigil Neuroscience Earnings Headlines

Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
William Blair Remains a Buy on Vigil Neuroscience Inc (VIGL)
See More Vigil Neuroscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vigil Neuroscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vigil Neuroscience and other key companies, straight to your email.

About Vigil Neuroscience

Vigil Neuroscience (NASDAQ:VIGL), a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

View Vigil Neuroscience Profile

More Earnings Resources from MarketBeat